≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Disorders of puberty, other/unspecified

DOID Endpoint Browser PheWeb

E4_PUBDISNAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

152

4. Check minimum number of events

None

152

5. Include endpoints

None

152

6. Filter based on genotype QC (FinnGen only)

144

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2778 2033 744
Only index persons 2125 1439 686
Unadjusted period prevalence (%)
Whole population 0.05 0.06 0.02
Only index persons 0.04 0.05 0.03
Median age at first event (years)
Whole population 9.61 7.65 14.97
Only index persons 10.35 8.12 15.01

-FinnGen-

Key figures

All Female Male
Number of individuals 144 111 33
Unadjusted period prevalence (%) 0.03 0.04 0.02
Median age at first event (years) 10.66 9.37 15.00

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
152
Matched controls
1520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E30.8
ICD-10 Finland
Other disorders of puberty
+∞
92.4
79
*
E30.9
ICD-10 Finland
Disorder of puberty, unspecified
1482.7
86.5
76
*
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
19.6
50.6
44
31
E30.09
ICD-10 Finland
Delayed puberty NOS
+∞
19.2
18
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
5.9
15.6
32
66
H03AA01
ATC
levothyroxine sodium; systemic
4.4
13.9
44
130
E30.1
ICD-10 Finland
Precocious puberty
55.1
13.1
15
*
L02AE02
ATC
leuprorelin; implant, parenteral
21.0
11.9
17
9
E34.35
ICD-10 Finland
Abnormal growth retardation
70.5
11.8
13
*
E30.00
ICD-10 Finland
Familial delayed puberty
+∞
11.6
11
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
30.6
10.9
14
5
E22.80
ICD-10 Finland
Central precocious puberty
117.8
10.6
11
*
Z51.80
ICD-10 Finland
Manipulation of puberty development with hormone therapy
+∞
9.5
9
*
H01AC01
ATC
somatropin; parenteral
+∞
9.5
9
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.0
8.7
28
82
G03FB08
ATC
dydrogesterone and estrogen; systemic
16.1
7.9
12
8
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
7.3
7
*
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
31.7
7.2
9
*
104
Kela drug reimbursment
Thyroid insufficiency
6.3
6.3
16
28
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.9
6.3
33
131
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.3
6
*
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
6.3
6
*
F82
ICD-10 Finland
Specific developmental disorder of motor function
9.2
6.2
12
14
E03.89
ICD-10 Finland
Other specified hypothyroidism
7.8
6.1
13
18

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
2.3e+00
2.7e+00
1.0e+50
—
—
3.4e+00
2.2e+00
cases:5.30%
controls:0.56%
cases:6.82%
controls:0.48%
cases:4.55%
controls:0.00%
—
—
—
—
cases:12.50%
controls:0.49%
cases:5.79%
controls:0.70%
7
7
125
1242
9
6
123
1243
6
0
126
1249
—
—
16
6
112
1221
7
8
114
1137
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
2.1e+00
2.1e+00
1.6e+00
—
1.8e+00
2.3e+00
2.1e+00
cases:18.18%
controls:2.56%
cases:19.70%
controls:2.88%
cases:5.30%
controls:1.12%
—
—
cases:5.30%
controls:0.88%
cases:24.22%
controls:3.10%
cases:27.27%
controls:4.28%
24
32
108
1217
26
36
106
1213
7
14
125
1235
—
7
11
125
1236
31
38
97
1189
33
49
88
1096
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
2.2e+00
2.7e+00
1.0e+50
—
—
3.6e+00
2.0e+00
cases:5.30%
controls:0.64%
cases:6.82%
controls:0.48%
cases:4.55%
controls:0.00%
—
—
—
—
cases:13.28%
controls:0.41%
cases:6.61%
controls:0.96%
7
8
125
1241
9
6
123
1243
6
0
126
1249
—
—
17
5
111
1222
8
11
113
1134
Outpatient Visit
OP [9202]
4.9e-01
6.0e-01
2.5e-01
5.4e+00
1.2e+00
1.3e+00
9.1e-01
cases:74.24%
controls:63.73%
cases:62.88%
controls:48.20%
cases:17.42%
controls:14.09%
cases:59.85%
controls:0.64%
cases:34.09%
controls:13.71%
cases:75.78%
controls:46.70%
cases:84.30%
controls:68.47%
98
796
34
453
83
602
49
647
23
176
109
1073
79
8
53
1241
45
171
87
1076
97
573
31
654
102
784
19
361
Medical doctor
Z2221 [2001311556]
1.0e+00
1.6e+00
—
1.0e+50
—
3.1e+00
1.5e+00
cases:10.61%
controls:4.08%
cases:6.82%
controls:1.52%
—
—
cases:3.79%
controls:0.00%
—
—
cases:10.16%
controls:0.49%
cases:11.57%
controls:2.97%
14
51
118
1198
9
19
123
1230
—
5
0
127
1249
—
13
6
115
1221
14
34
107
1111
Pediatric Endocrinology
OMOP4822030 [45756809]
1.1e+00
1.5e+00
—
—
1.9e+00
2.2e+00
1.7e+00
cases:9.09%
controls:3.36%
cases:12.12%
controls:2.96%
—
—
—
—
cases:3.79%
controls:0.56%
cases:23.44%
controls:3.34%
cases:19.83%
controls:4.45%
12
42
120
1207
16
37
116
1212
—
—
5
7
127
1240
30
41
98
1186
24
51
97
1094
Psychologist
Z2445 [2001311558]
1.8e+00
—
—
—
—
—
2.8e+00
cases:6.82%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:6.61%
controls:0.44%
9
15
123
1234
—
—
—
—
—
8
5
113
1140
Nonallergic asthma
J45.1 [45557625]
9.3e-01
2.0e+00
—
—
—
—
2.5e+00
cases:4.55%
controls:1.84%
cases:5.30%
controls:0.72%
—
—
—
—
—
—
—
—
cases:5.79%
controls:0.52%
6
23
126
1226
7
9
125
1240
—
—
—
—
7
6
114
1139
Paediatric neurology
421 [44777781]
1.0e+00
7.2e-01
1.7e+00
—
1.2e+00
1.0e+00
1.3e+00
cases:19.70%
controls:8.25%
cases:10.61%
controls:5.44%
cases:6.06%
controls:1.12%
—
—
cases:4.55%
controls:1.36%
cases:10.94%
controls:4.32%
cases:15.70%
controls:4.80%
26
103
106
1146
14
68
118
1181
8
14
124
1235
—
6
17
126
1230
14
53
114
1174
19
55
102
1090
Physiotherapist
Z3226 [2001311560]
1.7e+00
1.9e+00
—
—
—
2.3e+00
1.0e+00
cases:10.61%
controls:2.16%
cases:3.79%
controls:0.56%
—
—
—
—
—
—
cases:4.69%
controls:0.49%
cases:4.96%
controls:1.83%
14
27
118
1222
5
7
127
1242
—
—
—
6
6
122
1221
6
21
115
1124
Inpatient Hospital
21 [8717]
-1.8e-01
9.1e-01
1.7e+00
—
1.4e+00
1.1e+00
6.5e-01
cases:26.52%
controls:30.18%
cases:21.21%
controls:9.77%
cases:6.06%
controls:1.12%
—
—
cases:4.55%
controls:1.20%
cases:19.53%
controls:7.82%
cases:33.06%
controls:20.44%
35
377
97
872
28
122
104
1127
8
14
124
1235
—
6
15
126
1232
25
96
103
1131
40
234
81
911
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.1e+00
2.2e+00
—
—
—
1.8e+00
1.5e+00
cases:6.06%
controls:2.08%
cases:5.30%
controls:0.64%
—
—
—
—
—
—
cases:3.91%
controls:0.65%
cases:9.92%
controls:2.45%
8
26
124
1223
7
8
125
1241
—
—
—
5
8
123
1219
12
28
109
1117
Pediatric Medicine
37 [38004477]
4.3e-01
7.9e-01
4.1e-01
—
1.5e+00
1.2e+00
6.5e-01
cases:47.73%
controls:37.15%
cases:40.91%
controls:23.86%
cases:8.33%
controls:5.68%
—
—
cases:22.73%
controls:5.93%
cases:46.88%
controls:20.54%
cases:38.84%
controls:24.89%
63
464
69
785
54
298
78
951
11
71
121
1178
—
30
74
102
1173
60
252
68
975
47
285
74
860
Laboratory Visit
OMOP4822461 [32036]
1.6e-01
3.2e-01
1.2e+00
2.3e+00
7.9e-01
4.9e-01
2.9e-01
cases:20.45%
controls:18.01%
cases:21.21%
controls:16.41%
cases:12.88%
controls:4.24%
cases:4.55%
controls:0.48%
cases:6.82%
controls:3.21%
cases:23.44%
controls:15.81%
cases:38.84%
controls:32.23%
27
225
105
1024
28
205
104
1044
17
53
115
1196
6
6
126
1243
9
40
123
1207
30
194
98
1033
47
369
74
776
Measurement of bone age from hand and elbow using X-ray
NK6MA [2001308495]
—
—
—
1.0e+50
—
—
2.8e+00
—
—
—
—
—
—
cases:6.06%
controls:0.00%
—
—
—
—
cases:10.74%
controls:0.70%
—
—
—
8
0
124
1249
—
—
13
8
108
1137
Estradiol (E2) [Moles/volume] in Serum or Plasma by High sensitivity method
72873-3 [43534046]
2.3e+00
2.6e+00
—
—
—
—
—
cases:3.79%
controls:0.40%
cases:5.30%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
5
5
127
1244
7
5
125
1244
—
—
—
—
—
Supplier / Service Provider
OMOP5117446 [33004]
-9.8e-01
-2.8e-01
—
—
—
1.4e+00
2.6e+00
cases:8.33%
controls:19.46%
cases:5.30%
controls:6.89%
—
—
—
—
—
—
cases:4.69%
controls:1.14%
cases:12.40%
controls:1.05%
11
243
121
1006
7
86
125
1163
—
—
—
6
14
122
1213
15
12
106
1133
Outpatient Hospital
22 [8756]
7.9e-02
1.2e+00
2.0e+00
1.0e+50
—
1.3e+00
7.0e-01
cases:24.24%
controls:22.82%
cases:18.94%
controls:6.33%
cases:4.55%
controls:0.64%
cases:3.79%
controls:0.00%
—
—
cases:17.19%
controls:5.13%
cases:26.45%
controls:15.11%
32
285
100
964
25
79
107
1170
6
8
126
1241
5
0
127
1249
—
22
63
106
1164
32
173
89
972
Hypothyroidism, unspecified
E03.9 [45537945]
—
1.0e+50
—
—
—
—
2.5e+00
—
—
cases:4.55%
controls:0.00%
—
—
—
—
—
—
—
—
cases:9.92%
controls:0.87%
—
6
0
126
1249
—
—
—
—
12
10
109
1135
Other healthcare associate professional
Z3229 [2001311561]
1.5e+00
—
—
—
—
—
2.5e+00
cases:5.30%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.44%
7
16
125
1233
—
—
—
—
—
6
5
115
1140
Other hypothyroidism
E03 [45581337]
2.5e+00
—
—
—
—
—
—
cases:4.55%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
126
1244
—
—
—
—
—
—
Neuropsychological investigation
XA800 [2001300412]
2.1e+00
—
—
—
—
—
—
cases:6.82%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
9
11
123
1238
—
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
1.5e-01
7.3e-02
5.7e-01
2.1e+00
4.9e-01
1.7e-01
9.9e-02
cases:44.70%
controls:41.07%
cases:40.91%
controls:39.15%
cases:24.24%
controls:15.29%
cases:8.33%
controls:1.12%
cases:23.48%
controls:15.80%
cases:47.66%
controls:43.52%
cases:63.64%
controls:61.31%
59
513
73
736
54
489
78
760
32
191
100
1058
11
14
121
1235
31
197
101
1050
61
534
67
693
77
702
44
443
Obstetrics / Gynecology
16 [38004461]
-2.1e-01
1.1e+00
—
1.0e+50
—
1.7e+00
2.3e-01
cases:4.55%
controls:5.52%
cases:7.58%
controls:2.64%
—
—
cases:10.61%
controls:0.00%
—
—
cases:14.06%
controls:2.77%
cases:11.57%
controls:9.43%
6
69
126
1180
10
33
122
1216
—
14
0
118
1249
—
18
34
110
1193
14
108
107
1037
More than one and less than three hours
ZXE10 [2001311401]
6.2e-01
1.3e+00
—
—
—
—
1.6e+00
cases:9.09%
controls:5.12%
cases:5.30%
controls:1.44%
—
—
—
—
—
—
—
—
cases:10.74%
controls:2.36%
12
64
120
1185
7
18
125
1231
—
—
—
—
13
27
108
1118
Pediatric Cardiology
OMOP4821938 [45756805]
6.3e-01
8.9e-01
—
—
—
—
1.5e+00
cases:6.82%
controls:3.76%
cases:4.55%
controls:1.92%
—
—
—
—
—
—
—
—
cases:8.26%
controls:1.92%
9
47
123
1202
6
24
126
1225
—
—
—
—
10
22
111
1123
Psychosocial counselling and guidance
SPAT1307 [2001700408]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:7.44%
controls:1.75%
0
10
132
1239
—
—
—
—
—
9
20
112
1125
omeprazole; oral, parenteral
A02BC01 [21600096]
6.3e-01
1.0e+00
—
—
—
—
1.5e+00
cases:4.55%
controls:2.48%
cases:3.79%
controls:1.36%
—
—
—
—
—
—
—
—
cases:8.26%
controls:2.01%
6
31
126
1218
5
17
127
1232
—
—
—
—
10
23
111
1122
Base excess in Venous blood by calculation
1927-3 [3002032]
—
1.2e+00
—
—
—
1.1e+00
1.4e+00
—
—
cases:4.55%
controls:1.44%
—
—
—
—
—
—
cases:3.91%
controls:1.30%
cases:8.26%
controls:2.10%
—
6
18
126
1231
—
—
—
5
16
123
1211
10
24
111
1121
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
1.1e+00
—
—
—
1.1e+00
1.4e+00
—
—
cases:4.55%
controls:1.52%
—
—
—
—
—
—
cases:3.91%
controls:1.30%
cases:8.26%
controls:2.10%
—
6
19
126
1230
—
—
—
5
16
123
1211
10
24
111
1121
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
2.4e-01
9.8e-01
1.0e+00
—
9.3e-01
1.1e+00
1.2e+00
cases:6.82%
controls:5.44%
cases:8.33%
controls:3.28%
cases:3.79%
controls:1.36%
—
—
cases:3.79%
controls:1.52%
cases:9.38%
controls:3.26%
cases:17.36%
controls:5.68%
9
68
123
1181
11
41
121
1208
5
17
127
1232
—
5
19
127
1228
12
40
116
1187
21
65
100
1080
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
6.8e-01
5.5e-01
—
—
—
1.2e+00
8.1e-01
cases:10.61%
controls:5.68%
cases:6.06%
controls:3.60%
—
—
—
—
—
—
cases:10.16%
controls:3.26%
cases:11.57%
controls:5.50%
14
71
118
1178
8
45
124
1204
—
—
—
13
40
115
1187
14
63
107
1082
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
7.0e-01
9.7e-01
—
—
—
1.2e+00
7.3e-01
cases:11.36%
controls:6.00%
cases:10.61%
controls:4.32%
—
—
—
—
—
—
cases:13.28%
controls:4.40%
cases:22.31%
controls:12.14%
15
75
117
1174
14
54
118
1195
—
—
—
17
54
111
1173
27
139
94
1006
calcium (different salts in combination); oral
A12AA20 [21600872]
9.9e-01
8.6e-01
—
—
-1.0e+50
1.2e+00
1.2e+00
cases:6.82%
controls:2.64%
cases:5.30%
controls:2.32%
—
—
—
—
cases:0.00%
controls:0.48%
cases:6.25%
controls:1.87%
cases:10.74%
controls:3.67%
9
33
123
1216
7
29
125
1220
—
—
0
6
132
1241
8
23
120
1204
13
42
108
1103
Internal Medicine
11 [38004456]
4.1e-01
1.1e+00
—
—
—
4.2e-01
4.9e-01
cases:10.61%
controls:7.29%
cases:11.36%
controls:4.00%
—
—
—
—
—
—
cases:7.03%
controls:4.73%
cases:20.66%
controls:13.71%
14
91
118
1158
15
50
117
1199
—
—
—
9
58
119
1169
25
157
96
988
Pediatric Surgery
OMOP4822020 [45756819]
4.5e-01
7.8e-01
-1.0e+50
—
—
5.4e-01
9.5e-01
cases:12.88%
controls:8.65%
cases:6.06%
controls:2.88%
cases:0.00%
controls:0.64%
—
—
—
—
cases:5.47%
controls:3.26%
cases:15.70%
controls:6.72%
17
108
115
1141
8
36
124
1213
0
8
132
1241
—
—
7
40
121
1187
19
77
102
1068
Emergency Room Visit
ER [9203]
3.7e-01
9.0e-01
1.2e+00
—
—
6.2e-01
4.2e-01
cases:37.12%
controls:28.90%
cases:19.70%
controls:9.05%
cases:6.06%
controls:1.84%
—
—
—
—
cases:15.63%
controls:9.05%
cases:37.19%
controls:28.03%
49
361
83
888
26
113
106
1136
8
23
124
1226
—
—
20
111
108
1116
45
321
76
824
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
-1.2e-01
7.6e-01
-1.0e+50
—
—
6.6e-01
8.9e-01
cases:6.06%
controls:6.81%
cases:8.33%
controls:4.08%
cases:0.00%
controls:0.88%
—
—
—
—
cases:6.25%
controls:3.34%
cases:19.01%
controls:8.82%
8
85
124
1164
11
51
121
1198
0
11
132
1238
—
—
8
41
120
1186
23
101
98
1044
Telehealth
OMOP5556618 [722455]
2.9e-01
7.7e-01
—
—
—
8.4e-01
7.7e-01
cases:17.42%
controls:13.61%
cases:9.85%
controls:4.80%
—
—
—
—
—
—
cases:14.84%
controls:7.01%
cases:34.71%
controls:19.74%
23
170
109
1079
13
60
119
1189
—
—
—
19
86
109
1141
42
226
79
919
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
9835/3-C42.1 [44503066]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
132
1231
—
—
—
—
—
—
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
-9.8e-02
—
-1.0e+50
—
—
—
1.8e-01
cases:6.06%
controls:6.65%
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:6.61%
controls:5.59%
8
83
124
1166
—
0
5
132
1244
—
—
—
8
64
113
1081
Fracture of other toe
S92.5 [45565210]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
hydrocortisone and antiseptics
D07BA04 [21602146]
1.8e-01
—
—
—
—
—
8.5e-01
cases:4.55%
controls:3.84%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.18%
6
48
126
1201
—
—
—
—
—
6
25
115
1120
cisapride; oral, rectal
A03FA02 [21600485]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
0
5
132
1244
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
—
-1.0e+50
—
—
—
-1.0e+50
1.7e-01
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:4.13%
controls:3.49%
—
0
16
132
1233
—
—
—
0
9
128
1218
5
40
116
1105
Personal history of leukaemia
Z85.6 [45609980]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.16%
cases:0.00%
controls:1.44%
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:1.79%
cases:0.00%
controls:2.97%
0
27
132
1222
0
18
132
1231
—
—
0
7
132
1240
0
22
128
1205
0
34
121
1111
imiquimod
D06BB10 [21602092]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Remote contact by phone
ZYC01 [2001311579]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
132
1238
—
—
—
—
—
—
Bladder symptom/complaint other
U13 [2002001144]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
General counselling and advice on contraception
Z30.0 [45537624]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
6
128
1221
—
Bacteria identified in Urine by Culture
630-4 [3026008]
8.9e-01
-1.0e+50
—
—
—
—
5.0e-01
cases:4.55%
controls:1.92%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:5.79%
controls:3.58%
6
24
126
1225
0
7
132
1242
—
—
—
—
7
41
114
1104
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Deep bite
K07.23 [2000502769]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
8
132
1241
—
0
5
132
1242
—
—
Knee and lower leg MRI examination with high intensity magnet
NG1BG [2001308056]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
11
121
1134
Physical Medicine And Rehabilitation
25 [38004468]
5.0e-01
—
—
—
—
—
3.6e-01
cases:5.30%
controls:3.28%
—
—
—
—
—
—
—
—
—
—
cases:8.26%
controls:5.94%
7
41
125
1208
—
—
—
—
—
10
68
111
1077
tinzaparin; parenteral
B01AB10 [21600981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Unspecified haematuria
R31 [45553726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
—
—
alprazolam; oral
N05BA12 [21604577]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Cough
R05 [2002000886]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.61%
controls:4.10%
—
—
—
—
—
—
8
47
113
1098
Thrombin time
3243-3 [3036489]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.70%
0
14
132
1235
0
7
132
1242
—
—
—
0
6
128
1221
0
8
121
1137
Contraception intrauterine
W12 [2002001212]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Pain localized to upper abdomen
R10.1 [45568111]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
0
5
132
1244
—
—
—
—
0
11
121
1134
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
21
132
1228
—
—
—
—
0
7
128
1220
—
COVID-19, virus not identified
U07.2 [45756094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
4.0e-01
—
—
—
—
—
1.2e-01
cases:5.30%
controls:3.60%
—
—
—
—
—
—
—
—
—
—
cases:5.79%
controls:5.15%
7
45
125
1204
—
—
—
—
—
7
59
114
1086
long-acting sulfonamides - combinations
J01ED20 [21602959]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.44%
—
—
—
—
—
0
5
128
1222
0
5
121
1140
Cystitis, unspecified
N30.9 [45606488]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:4.64%
cases:0.00%
controls:4.24%
cases:0.00%
controls:1.60%
—
—
cases:0.00%
controls:1.12%
cases:0.00%
controls:4.89%
cases:0.00%
controls:6.20%
0
58
132
1191
0
53
132
1196
0
20
132
1229
—
0
14
132
1233
0
60
128
1167
0
71
121
1074
Pharmacologic abortion
LCH11 [2001306623]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Exposure to other specified factors
X58 [45756411]
—
-1.0e+50
—
—
—
—
9.3e-01
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.01%
—
0
6
132
1243
—
—
—
—
6
23
115
1122
Counselling related to known health issue
SPAT1310 [2001700411]
2.7e-01
—
—
—
-1.0e+50
—
4.2e-01
cases:4.55%
controls:3.52%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
cases:10.74%
controls:7.34%
6
44
126
1205
—
—
—
0
6
132
1241
—
13
84
108
1061
Examination of eyes and vision
Z01.0 [45566391]
4.8e-01
—
—
—
—
—
—
cases:6.82%
controls:4.32%
—
—
—
—
—
—
—
—
—
—
—
—
9
54
123
1195
—
—
—
—
—
—
hepatitis vaccines - combinations
J07BC20 [21601340]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
10
121
1135
Allergic rhinitis due to pollen
J30.10 [2000502594]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
0
5
132
1244
—
—
0
12
128
1215
—
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
7.2e-01
1.2e+00
—
—
—
5.1e-01
5.6e-02
cases:9.09%
controls:4.64%
cases:6.82%
controls:2.24%
—
—
—
—
—
—
cases:5.47%
controls:3.34%
cases:10.74%
controls:10.22%
12
58
120
1191
9
28
123
1221
—
—
—
7
41
121
1186
13
117
108
1028
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.05%
—
—
—
—
—
—
5
12
116
1133
phenylephrine, combinations
R01BA53 [21603214]
2.7e-01
—
—
—
—
-1.0e+50
—
cases:4.55%
controls:3.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
6
44
126
1205
—
—
—
—
0
7
128
1220
—
EKG study
11524-6 [3013512]
—
—
—
—
—
—
8.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.83%
—
—
—
—
—
—
5
21
116
1124
enalapril and diuretics
C09BA02 [21601804]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.61%
0
6
132
1243
0
6
132
1243
—
—
—
0
6
128
1221
0
7
121
1138
hydrocortisone
C05AA01 [21601608]
2.2e-01
5.2e-02
—
—
—
3.8e-01
1.5e-01
cases:12.12%
controls:9.93%
cases:3.79%
controls:3.60%
—
—
—
—
—
—
cases:4.69%
controls:3.26%
cases:9.09%
controls:7.95%
16
124
116
1125
5
45
127
1204
—
—
—
6
40
122
1187
11
91
110
1054
Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
3198-9 [3011547]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Feeling depressed
P03 [2002000800]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.22%
—
—
—
—
—
—
5
14
116
1131
Other blockage of nerve
WX290 [2001310792]
—
—
—
—
—
—
2.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.74%
controls:8.82%
—
—
—
—
—
—
13
101
108
1044
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
8
121
1137
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.05%
—
—
—
—
—
—
5
12
116
1133
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
0
18
132
1231
—
—
—
0
8
128
1219
—
hydrocortisone buteprate
D07AB11 [21602115]
2.2e-01
5.2e-02
—
—
—
3.8e-01
1.5e-01
cases:12.12%
controls:9.93%
cases:3.79%
controls:3.60%
—
—
—
—
—
—
cases:4.69%
controls:3.26%
cases:9.09%
controls:7.95%
16
124
116
1125
5
45
127
1204
—
—
—
6
40
122
1187
11
91
110
1054
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.2e-01
—
—
—
—
—
-9.5e-02
cases:6.06%
controls:4.08%
—
—
—
—
—
—
—
—
—
—
cases:7.44%
controls:8.12%
8
51
124
1198
—
—
—
—
—
9
93
112
1052
Urticaria, unspecified
L50.9 [45562541]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Caries limited to enamel
K02.0 [45576967]
8.2e-01
7.3e-01
—
—
—
—
5.0e-01
cases:6.82%
controls:3.12%
cases:4.55%
controls:2.24%
—
—
—
—
—
—
—
—
cases:11.57%
controls:7.34%
9
39
123
1210
6
28
126
1221
—
—
—
—
14
84
107
1061
Abdominal pain/cramps general
D01 [2002000300]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
5
128
1222
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
3.6e-02
—
—
—
—
—
—
cases:5.30%
controls:5.12%
—
—
—
—
—
—
—
—
—
—
—
—
7
64
125
1185
—
—
—
—
—
—
Manipulation of puberty development with hormone therapy
Z51.80 [2000503764]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:3.91%
controls:0.00%
cases:5.79%
controls:0.00%
—
—
—
—
—
5
0
123
1227
7
0
114
1145
Chronic ischaemic heart disease
I25 [45581765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Celiac disease serology panel - Serum
94494-2 [36660697]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
0
7
132
1242
—
—
—
0
8
128
1219
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
9.1e-02
6.3e-01
6.6e-01
—
—
7.0e-01
3.4e-01
cases:15.91%
controls:14.73%
cases:18.18%
controls:10.57%
cases:3.79%
controls:2.00%
—
—
—
—
cases:16.41%
controls:8.88%
cases:23.97%
controls:18.34%
21
184
111
1065
24
132
108
1117
5
25
127
1224
—
—
21
109
107
1118
29
210
92
935
Preventive oral care by dental hygienist
SCF02 [2001310319]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:0.79%
—
—
—
—
—
—
5
9
116
1136
Pediatric Infectious Diseases
OMOP4822027 [45756812]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
Clarification/discussion RFE/demand
-48 [2002000119]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
7
132
1242
0
5
132
1244
—
—
—
—
0
13
121
1132
oxcarbazepine; oral
N03AF02 [21604418]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
9
132
1240
—
—
—
0
5
128
1222
—
Trichilemmal cyst
L72.1 [45596386]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
zolmitriptan; nasal, oral
N02CC03 [21604378]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
Preventive oral health care, short
SCA01 [2001310302]
5.3e-02
8.8e-02
—
—
—
—
-4.7e-02
cases:15.91%
controls:15.21%
cases:8.33%
controls:7.69%
—
—
—
—
—
—
—
—
cases:19.01%
controls:19.74%
21
190
111
1059
11
96
121
1153
—
—
—
—
23
226
98
919
Pediatric Hematology-Oncology
OMOP4822028 [45756811]
2.1e-01
7.9e-01
—
—
-1.0e+50
7.1e-01
—
cases:5.30%
controls:4.32%
cases:5.30%
controls:2.48%
—
—
—
—
cases:0.00%
controls:0.96%
cases:3.91%
controls:1.96%
—
—
7
54
125
1195
7
31
125
1218
—
—
0
12
132
1235
5
24
123
1203
—
hydrocortisone
A07EA02 [21600654]
2.2e-01
5.2e-02
—
—
—
3.8e-01
1.5e-01
cases:12.12%
controls:9.93%
cases:3.79%
controls:3.60%
—
—
—
—
—
—
cases:4.69%
controls:3.26%
cases:9.09%
controls:7.95%
16
124
116
1125
5
45
127
1204
—
—
—
6
40
122
1187
11
91
110
1054
rosuvastatin; oral
C10AA07 [21601862]
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.12%
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
0
14
132
1235
—
0
5
132
1244
—
—
—
—
Impetigo [any organism] [any site]
L01.0 [45572243]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
pH of Specimen
17433-4 [3019225]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
9
121
1136
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Weakness/tiredness general
A04 [2002000145]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:1.66%
0
7
132
1242
—
—
—
—
—
6
19
115
1126
Acute lymphoblastic leukaemia [ALL]
C91.0 [45537873]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:3.20%
cases:0.00%
controls:1.12%
—
—
cases:0.00%
controls:1.12%
cases:0.00%
controls:2.93%
cases:0.00%
controls:3.58%
—
0
40
132
1209
0
14
132
1235
—
0
14
132
1233
0
36
128
1191
0
41
121
1104
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:1.48%
—
—
—
—
—
—
6
17
115
1128
prednisolone
A07EA01 [21600653]
3.5e-01
8.8e-01
—
—
—
—
-1.6e-01
cases:7.58%
controls:5.44%
cases:3.79%
controls:1.60%
—
—
—
—
—
—
—
—
cases:4.13%
controls:4.80%
10
68
122
1181
5
20
127
1229
—
—
—
—
5
55
116
1090
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
latanoprost
S01EE01 [21603710]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Dietary counselling and surveillance
Z71.3 [45552101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
132
1239
—
—
—
—
—
—
Hand and fingers X-ray examination
ND2AA [2001307607]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
General health counselling
SPAT1312 [2001700413]
—
—
—
—
—
—
3.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.22%
controls:10.04%
—
—
—
—
—
—
16
115
105
1030
terbutaline; oral, parenteral
R03CC03 [21603313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
6.6e-01
—
—
—
—
—
9.8e-01
cases:4.55%
controls:2.40%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:1.92%
6
30
126
1219
—
—
—
—
—
6
22
115
1123
Peanut recombinant (rAra h) 2 IgE Ab [Units/volume] in Serum
58778-2 [40761872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
Viral warts
B07 [45532863]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
combinations of corticosteroids
D07XB30 [21602188]
3.2e-01
8.3e-01
—
—
—
—
8.9e-02
cases:12.88%
controls:9.69%
cases:6.06%
controls:2.72%
—
—
—
—
—
—
—
—
cases:9.09%
controls:8.38%
17
121
115
1128
8
34
124
1215
—
—
—
—
11
96
110
1049
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
132
1227
—
—
—
—
—
—
Therapeutic discussion
SPAT1240 [2001700341]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
6
128
1221
—
Deposits [accretions] on teeth betel
K03.65 [2000502690]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Pain/tenderness of skin
S01 [2002000966]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
7.9e-01
—
-1.0e+50
—
—
8.6e-01
4.3e-01
cases:6.82%
controls:3.20%
—
—
cases:0.00%
controls:0.40%
—
—
—
—
cases:4.69%
controls:2.04%
cases:7.44%
controls:4.98%
9
40
123
1209
—
0
5
132
1244
—
—
6
25
122
1202
9
57
112
1088
Coagulation factor X activity actual/normal in Platelet poor plasma by Coagulation assay
3218-5 [3004409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.70%
0
13
132
1236
0
7
132
1242
—
—
—
0
6
128
1221
0
8
121
1137
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:1.05%
0
10
132
1239
—
—
—
—
0
5
128
1222
0
12
121
1133
Pulmonary Disease
29 [38004472]
—
—
—
—
—
1.1e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:3.91%
controls:1.30%
cases:7.44%
controls:2.01%
—
—
—
—
—
5
16
123
1211
9
23
112
1122
epinephrine; parenteral
C01CA24 [21600303]
8.3e-01
—
—
—
—
—
—
cases:3.79%
controls:1.68%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
127
1228
—
—
—
—
—
—
Hyperkinetic disorder
P81 [2002000875]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
8
121
1137
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.4e-01
1.3e+00
—
—
—
1.3e+00
5.3e-01
cases:9.85%
controls:6.00%
cases:4.55%
controls:1.28%
—
—
—
—
—
—
cases:7.81%
controls:2.36%
cases:9.92%
controls:6.11%
13
75
119
1174
6
16
126
1233
—
—
—
10
29
118
1198
12
70
109
1075
Precocious puberty
E30.1 [45581364]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.00%
cases:4.13%
controls:0.00%
—
—
—
—
—
7
0
121
1227
5
0
116
1145
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
2.2e-01
—
—
—
—
—
—
cases:4.55%
controls:3.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
46
126
1203
—
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.5e-01
9.2e-01
-1.0e+50
—
—
5.6e-01
3.9e-01
cases:9.09%
controls:7.93%
cases:12.12%
controls:5.20%
cases:0.00%
controls:1.12%
—
—
—
—
cases:7.03%
controls:4.16%
cases:10.74%
controls:7.51%
12
99
120
1150
16
65
116
1184
0
14
132
1235
—
—
9
51
119
1176
13
86
108
1059
topiramate; oral
N03AX11 [21604433]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
Vulval symptom/complaint
X16 [2002001301]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
2.7e-01
—
—
—
—
-1.0e+50
—
cases:4.55%
controls:3.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
6
44
126
1205
—
—
—
—
0
6
128
1221
—
Lumbar puncture
TAB00 [2001300538]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
6.6e-01
—
—
—
-1.0e+50
—
4.2e-01
cases:4.55%
controls:2.40%
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
cases:8.26%
controls:5.59%
6
30
126
1219
—
—
—
0
7
132
1240
—
10
64
111
1081
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
0
11
132
1238
—
—
—
—
—
Intubation
WX704 [2001310820]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
10
132
1239
—
—
—
—
—
0
6
121
1139
Monitoring of normal pregnancy
SPAT1196 [2001700297]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
7
121
1138
gestodene and ethinylestradiol
G03AB06 [21602494]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Streptococcal tonsillitis
J03.0 [45601114]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
9
132
1240
—
—
—
—
—
0
7
121
1138
Headache
R51.80 [2000503603]
—
-1.0e+50
—
—
—
1.9e+00
7.0e-01
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:4.69%
controls:0.73%
cases:4.13%
controls:2.10%
—
0
9
132
1240
—
—
—
6
9
122
1218
5
24
116
1121
Thorax X-ray examination
GD1AA [2001303617]
5.7e-01
1.6e+00
—
—
—
—
8.4e-01
cases:6.06%
controls:3.52%
cases:6.06%
controls:1.28%
—
—
—
—
—
—
—
—
cases:8.26%
controls:3.76%
8
44
124
1205
8
16
124
1233
—
—
—
—
10
43
111
1102
escitalopram; oral
N06AB10 [21604718]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
132
1237
—
—
—
—
—
—
General and Unspecified, Result test/procedure
A60 [2002000194]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
pH of Urine by Test strip
5803-2 [3022621]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.22%
0
7
132
1242
—
—
—
—
—
0
14
121
1131
Chalazion
H00.1 [45542919]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Transurethral resection of prostate
KED22 [2001306138]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
glimepiride; oral
A10BB12 [21600761]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
7
121
1138
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Other childhood emotional disorders
F93.89 [2000502046]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.05%
—
—
—
—
—
—
5
12
116
1133
fluticasone; inhalant
R03BA05 [21603288]
-2.3e-01
1.1e+00
—
—
—
7.4e-01
5.8e-01
cases:5.30%
controls:6.57%
cases:6.06%
controls:2.08%
—
—
—
—
—
—
cases:5.47%
controls:2.69%
cases:5.79%
controls:3.32%
7
82
125
1167
8
26
124
1223
—
—
—
7
33
121
1194
7
38
114
1107
Granulocytes [#/volume] in Blood
30394-1 [3035715]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
7
121
1138
Necrosis of pulp
K04.1 [45572186]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
17
121
1128
levocabastine; nasal
R01AC02 [21605034]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
8
132
1241
—
—
—
—
—
0
6
121
1139
Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
3216-9 [3020427]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.68%
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
0
21
132
1228
—
—
0
5
132
1242
—
—
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.44%
—
—
—
—
—
0
5
128
1222
0
5
121
1140
Alpha tocopherol [Moles/volume] in Serum or Plasma
14590-4 [3000208]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Chronic mucoid otitis media
H65.3 [45567124]
7.9e-01
—
—
—
—
—
-1.0e+50
cases:3.79%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
5
22
127
1227
—
—
—
—
—
0
7
121
1138
loratadine; oral
R06AX13 [21603514]
5.8e-01
-1.0e+50
—
—
—
—
—
cases:3.79%
controls:2.16%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
5
27
127
1222
0
7
132
1242
—
—
—
—
—
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
132
1236
—
—
—
—
—
—
Hyperplasia of prostate
N40 [45563015]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
In Home Supportive Care Agency
253Z00000X [38004206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.61%
controls:3.23%
—
—
—
—
—
—
8
37
113
1108
Audiology
64 [38004489]
5.9e-01
—
—
—
—
8.0e-01
7.6e-01
cases:4.55%
controls:2.56%
—
—
—
—
—
—
—
—
cases:3.91%
controls:1.79%
cases:5.79%
controls:2.79%
6
32
126
1217
—
—
—
—
5
22
123
1205
7
32
114
1113
General Practice
1 [38004446]
3.3e-01
3.9e-01
—
—
—
6.7e-01
4.4e-01
cases:10.61%
controls:7.85%
cases:4.55%
controls:3.12%
—
—
—
—
—
—
cases:4.69%
controls:2.44%
cases:14.88%
controls:10.13%
14
98
118
1151
6
39
126
1210
—
—
—
6
30
122
1197
18
116
103
1029
Atopic dermatitis
L20 [45557698]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
10
121
1135
Other psychiatric treatment contact
IGY99 [2001304323]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
fluticasone furoate; nasal
R01AD12 [21605053]
3.2e-01
—
—
—
—
—
5.4e-02
cases:7.58%
controls:5.60%
—
—
—
—
—
—
—
—
—
—
cases:7.44%
controls:7.07%
10
70
122
1179
—
—
—
—
—
9
81
112
1064
Demanding placement of orthodontic arch wire
SJD30 [2001310440]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
6
132
1243
—
—
—
—
0
5
128
1222
—
Protein [Mass/volume] in Urine
2888-6 [3037121]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
0
10
132
1239
0
9
132
1240
—
—
—
—
—
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
1.2e+00
1.2e+00
—
—
—
1.4e+00
9.4e-01
cases:8.33%
controls:2.64%
cases:5.30%
controls:1.68%
—
—
—
—
—
—
cases:4.69%
controls:1.14%
cases:8.26%
controls:3.41%
11
33
121
1216
7
21
125
1228
—
—
—
6
14
122
1213
10
39
111
1106
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
132
1239
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
9.6e-01
1.1e+00
—
—
—
—
3.6e-02
cases:6.06%
controls:2.40%
cases:4.55%
controls:1.52%
—
—
—
—
—
—
—
—
cases:5.79%
controls:5.59%
8
30
124
1219
6
19
126
1230
—
—
—
—
7
64
114
1081
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
11
121
1134
measles, combinations with mumps, rubella and varicella, live attenuated
J07BD54 [21601346]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
0
10
132
1239
—
—
—
—
—
0
11
121
1134
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.61%
controls:2.71%
—
—
—
—
—
—
8
31
113
1114
Fall on same level involving ice and snow
W00 [45756242]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:0.79%
—
—
—
—
—
—
5
9
116
1136
Otitis externa
H60 [45581713]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
amitriptyline and psycholeptics
N06CA01 [21604789]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
—
—
Shoulder symptom/complaint
L08 [2002000632]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
0
5
132
1244
—
—
—
—
0
8
128
1219
—
androstanolone
G03BB02 [21602513]
—
1.0e+50
—
—
—
—
1.0e+50
—
—
cases:3.79%
controls:0.00%
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.00%
—
5
0
127
1249
—
—
—
—
6
0
115
1145
Acute atopic conjunctivitis
H10.1 [45605605]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
132
1240
—
—
—
—
—
—
Accelerated psychiatric treatment contact
IGY01 [2001304321]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
7
128
1220
—
Knee symptom/complaint
L15 [2002000639]
—
-1.0e+50
—
—
—
—
7.8e-01
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:6.61%
controls:3.14%
—
0
7
132
1242
—
—
—
—
8
36
113
1109
Other preventive procedure
-49 [2002000120]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Headache
R51 [45558474]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Intravenous general anesthesia
WX404 [2001310807]
1.3e-01
1.4e+00
—
—
—
—
1.5e+00
cases:6.06%
controls:5.36%
cases:3.79%
controls:0.96%
—
—
—
—
—
—
—
—
cases:7.44%
controls:1.83%
8
67
124
1182
5
12
127
1237
—
—
—
—
9
21
112
1124
ephedrine; oral
R03CA02 [21603304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
7
121
1138
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
8
121
1137
betamethasone
C05AA05 [21601610]
6.6e-01
—
—
—
—
—
4.5e-01
cases:4.55%
controls:2.40%
—
—
—
—
—
—
—
—
—
—
cases:5.79%
controls:3.76%
6
30
126
1219
—
—
—
—
—
7
43
114
1102
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Other specifed ventricular septal defect
Q21.08 [2000503268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.52%
0
14
132
1235
0
8
132
1241
—
—
—
0
6
128
1221
0
6
121
1139
Examination and observation for unspecified reason
Z04.9 [45605102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
ABO and Rh group [Type] in Blood
882-1 [3003694]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
0
15
132
1234
—
—
—
—
—
Coloscopy
UJF32 [2001305029]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
5
128
1222
—
Chronic hypertension
205 [2001600203]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Left side
ZXA05 [2001311347]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
cases:5.79%
controls:1.22%
—
0
10
132
1239
—
—
—
—
7
14
114
1131
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
132
1238
—
—
—
—
—
—
Umbilical hernia without obstruction or gangrene
K42.9 [45591589]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.05%
—
—
—
—
—
—
5
12
116
1133
valaciclovir; oral
J05AB11 [21603137]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Examination of ears and hearing
Z01.1 [45547279]
9.9e-02
-1.0e+50
—
—
—
—
1.4e+00
cases:3.79%
controls:3.44%
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
cases:6.61%
controls:1.66%
5
43
127
1206
0
15
132
1234
—
—
—
—
8
19
113
1126
Abdominal ultrasound examination
JN3AE [2001305555]
1.0e+00
—
—
—
—
—
—
cases:4.55%
controls:1.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
126
1228
—
—
—
—
—
—
Health examination of person liable for military service
SPAT1321 [2001700422]
—
—
—
—
—
—
-2.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:6.29%
—
—
—
—
—
—
6
72
115
1073
salbutamol; oral, parenteral
R03CC02 [21603312]
4.6e-01
—
—
—
—
-1.0e+50
-1.0e+50
cases:12.12%
controls:8.01%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
cases:0.00%
controls:1.57%
16
100
116
1149
—
—
—
—
0
12
128
1215
0
18
121
1127
Cystoscopy
UKC02 [2001306005]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:0.44%
—
—
—
—
—
—
5
5
116
1140
naproxcinod
M01AE18 [40254094]
1.7e-01
5.2e-02
—
—
-1.0e+50
—
1.8e-02
cases:16.67%
controls:14.49%
cases:4.55%
controls:4.32%
—
—
—
—
cases:0.00%
controls:0.56%
—
—
cases:10.74%
controls:10.57%
22
181
110
1068
6
54
126
1195
—
—
0
7
132
1240
—
13
121
108
1024
finasteride; oral
D11AX10 [21602350]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Cat dander IgE Ab [Units/volume] in Serum
6833-8 [3023430]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
9
121
1136
dextromethorphan, combinations; oral
N07XX59 [43534835]
2.7e-01
—
—
—
—
-1.0e+50
-1.0e+50
cases:4.55%
controls:3.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.52%
6
44
126
1205
—
—
—
—
0
6
128
1221
0
6
121
1139
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
6.2e-01
9.3e-01
—
—
—
3.5e-01
4.9e-02
cases:9.09%
controls:5.12%
cases:7.58%
controls:3.12%
—
—
—
—
—
—
cases:6.25%
controls:4.48%
cases:12.40%
controls:11.88%
12
64
120
1185
10
39
122
1210
—
—
—
8
55
120
1172
15
136
106
1009
Periodontal treatment by dental hygienist
SDE02 [2001310350]
9.9e-01
—
—
—
—
—
4.3e-01
cases:3.79%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
cases:5.79%
controls:3.84%
5
18
127
1231
—
—
—
—
—
7
44
114
1101
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
-1.0e+50
—
—
—
—
—
1.2e+00
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.22%
0
20
132
1229
—
—
—
—
—
5
14
116
1131
Gynaecological examination (general)(routine)
Z01.4 [45542395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
132
1241
—
—
—
—
—
—
Supraglottic ventilation device
WX702 [2001310818]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Abnormality of white blood cells, not elsewhere classified
R72 [45602037]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
Genetic counselling
Z31.5 [45590715]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
5
128
1222
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
8
121
1137
Rash localized
S06 [2002000971]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.79%
—
—
—
—
—
0
5
128
1222
0
9
121
1136
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
0
6
132
1243
—
—
—
—
0
13
121
1132
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
132
1240
—
—
—
—
—
—
Dermatitis due to ingested food
L27.2 [45596371]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
5
128
1222
—
Basic examination of mouth
SAA02 [2001310275]
-7.2e-02
-2.5e-01
—
—
—
-3.2e-01
-1.1e-01
cases:15.91%
controls:16.89%
cases:8.33%
controls:10.49%
—
—
—
—
—
—
cases:7.03%
controls:9.45%
cases:27.27%
controls:29.52%
21
211
111
1038
11
131
121
1118
—
—
—
9
116
119
1111
33
338
88
807
Other developmental disorders of speech and language
F80.8 [45566856]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.53%
—
—
—
—
—
—
6
29
115
1116
quetiapine; oral
N05AH04 [21604544]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:1.22%
—
—
—
—
—
—
5
14
116
1131
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
F71.0 [45576559]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Localized oedema
R60.0 [45597193]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
—
Other and unspecified convulsions
R56.8 [45602033]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
6
132
1243
—
—
—
0
5
128
1222
—
Hypertension uncomplicated
K86 [2002000613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
7
121
1138
OTHER EXAMINATIONS, PROCEDURES, TREATMENT ETC.
SPAT1248 [2001700349]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Ulcerative colitis, unspecified
K51.9 [45605941]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
ofloxacin; oral, parenteral
J01MA01 [21603008]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
—
Incomplete uterovaginal prolapse
N81.2 [45596883]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Presence of electronic cardiac devices
Z95.0 [45571406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
9
121
1136
Extensive health check-up on fifth grade
SPAT1385 [2001700485]
1.5e-01
—
—
—
—
—
-2.3e-01
cases:3.79%
controls:3.28%
—
—
—
—
—
—
—
—
—
—
cases:4.13%
controls:5.15%
5
41
127
1208
—
—
—
—
—
5
59
116
1086
hydrocortisone and antiinfectives
S02CA03 [21605175]
4.2e-01
—
—
—
—
—
—
cases:4.55%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
38
126
1211
—
—
—
—
—
—
budesonide; nasal
R01AD05 [21605047]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
Audiometric test
21727005 [4071702]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
5
132
1244
—
—
—
0
6
128
1221
—
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.0e+00
—
—
—
—
—
8.5e-01
cases:3.79%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.18%
5
17
127
1232
—
—
—
—
—
6
25
115
1120
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
—
—
—
—
—
—
0
20
121
1125
Removal of fixed orthodontic appliance with at least 7 brackets
SJC50 [2001310435]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
5
132
1244
—
—
—
0
6
128
1221
—
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:2.80%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
0
35
132
1214
—
—
—
0
6
132
1241
—
—
Juvenile idiopathic scoliosis
M41.1 [45601442]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:1.40%
0
7
132
1242
0
7
132
1242
—
—
—
0
8
128
1219
0
16
121
1129
Diabetes mellitus screening
171183004 [4064918]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:1.22%
—
—
—
—
—
0
6
128
1221
0
14
121
1131
Adenotonsillectomy
EMB20 [2001302267]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Routine child health examination
Z00.1 [45561606]
-8.6e-02
1.5e-01
—
—
-1.0e+50
9.1e-01
3.0e-01
cases:10.61%
controls:11.45%
cases:6.06%
controls:5.28%
—
—
—
—
cases:0.00%
controls:0.56%
cases:6.25%
controls:2.61%
cases:10.74%
controls:8.21%
14
143
118
1106
8
66
124
1183
—
—
0
7
132
1240
8
32
120
1195
13
94
108
1051
Dermatitis, unspecified
L30.9 [45572271]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
132
1236
—
—
—
—
—
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Specific gravity of Urine by Test strip
5811-5 [3000330]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
5
132
1244
—
—
—
—
—
0
6
121
1139
azelastine; nasal
R01AC03 [21605035]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
7
132
1242
—
—
—
0
6
128
1221
—
Two-surface restoration
SFA20 [2001310359]
4.1e-01
6.9e-01
—
—
—
—
-9.4e-02
cases:6.82%
controls:4.64%
cases:6.82%
controls:3.52%
—
—
—
—
—
—
—
—
cases:12.40%
controls:13.45%
9
58
123
1191
9
44
123
1205
—
—
—
—
15
154
106
991
Laparoscopic appendectomy
JEA01 [2001304803]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
—
—
—
-1.0e+50
—
8.2e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
cases:9.92%
controls:4.63%
—
—
—
—
0
6
132
1241
—
12
53
109
1092
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
—
1.2e+00
—
—
—
1.3e+00
1.3e+00
—
—
cases:4.55%
controls:1.44%
—
—
—
—
—
—
cases:3.91%
controls:1.06%
cases:5.79%
controls:1.57%
—
6
18
126
1231
—
—
—
5
13
123
1214
7
18
114
1127
Tooth plaque
K03.66 [2000502691]
8.7e-01
—
—
—
—
—
5.6e-01
cases:6.82%
controls:2.96%
—
—
—
—
—
—
—
—
—
—
cases:7.44%
controls:4.37%
9
37
123
1212
—
—
—
—
—
9
50
112
1095
Endomysium IgG Ab [Titer] in Serum
49726-3 [3032773]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
132
1243
—
—
—
—
—
—
Volume in Urine collected for unspecified duration
19153-6 [3004775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
121
1140
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
121
1139
Extensive initial psychiatric evaluation
IBA04 [2001304046]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
6
132
1243
—
—
—
0
6
128
1221
—
Pediatric Nephrology
OMOP4822026 [45756813]
—
—
—
—
—
1.7e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.91%
controls:0.73%
cases:4.13%
controls:0.61%
—
—
—
—
—
5
9
123
1218
5
7
116
1138
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
6
128
1221
—
isotretinoin; oral
D10BA01 [21602320]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
6
132
1243
—
—
—
0
5
128
1222
—
Inpatient Visit
IP [9201]
8.8e-01
—
—
—
—
-1.0e+50
—
cases:3.79%
controls:1.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
5
20
127
1229
—
—
—
—
0
13
128
1214
—
Preventive oral health care
SCA02 [2001310303]
-1.3e-01
6.6e-01
—
—
—
—
3.7e-01
cases:4.55%
controls:5.12%
cases:4.55%
controls:2.40%
—
—
—
—
—
—
—
—
cases:9.92%
controls:7.07%
6
64
126
1185
6
30
126
1219
—
—
—
—
12
81
109
1064
Amblyopia ex anopsia
H53.0 [45581704]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
0
6
132
1243
—
—
—
—
0
7
121
1138
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
7.0e-01
—
—
—
1.3e+00
1.3e+00
—
—
cases:3.79%
controls:1.92%
—
—
—
—
—
—
cases:4.69%
controls:1.30%
cases:6.61%
controls:1.92%
—
5
24
127
1225
—
—
—
6
16
122
1211
8
22
113
1123
gabapentin; oral
N02BF01 [955005]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
6
132
1243
—
—
—
0
6
128
1221
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—
General Practice Dentistry
1223G0001X [38003675]
1.1e+00
1.3e+00
—
—
—
—
—
cases:4.55%
controls:1.52%
cases:4.55%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
6
19
126
1230
6
16
126
1233
—
—
—
—
—
Administration of medicine
SPAT1254 [2001700355]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.44%
controls:4.19%
—
—
—
—
—
—
9
48
112
1097
Chronic tonsillitis
J35.0 [45548113]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
0
5
132
1244
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
0
10
132
1239
—
—
—
—
—
Fracture of other finger
S62.6 [45564362]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
8
121
1137
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
F70.0 [45595920]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
7
132
1242
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
73
7.57
24.77
3.9
1.9
4.93
6.09
u/l
0.36
30
47
43
82
6.92
23.13
3.7
1.9
10.31
14.63
iu/l
0.49
34
58
31
63
5.93
15.29
2.5
1.9
6.32
10.38
nmol/l
1.33
25
55
17
13
14.54
10.45
5.6
1.3
28.44
22.54
nmol/l
0.71
17
13
14
19
7.99
6.58
1.3
1.8
21.19
20.17
ng/l
0.07
14
19
10
7
15.16
6.49
2.0
2.6
4.60
3.27
nmol/l
—
10
7
24
93
2.88
4.75
2.1
1.5
550.88
336.59
mu/l
0.58
24
88
128
1021
2.61
4.63
7.2
4.0
14.76
14.45
pmol/l
0.72
117
917
44
233
2.25
4.56
4.5
2.6
612.67
577.74
mosm/kgh2o
0.35
39
200
46
249
2.22
4.51
1.5
1.5
18.11
19.28
nmol/l
0.22
38
219
62
378
2.08
4.48
1.8
1.6
90.37
92.29
pmol/l
0.14
34
177
102
760
2.04
4.09
8.2
6.7
101.42
90.96
u/l
0.72
96
717
97
718
1.97
3.86
12.3
8.1
0.52
0.54
e9/l
0.33
87
614
73
493
1.92
3.81
9.7
8.6
—
—
—
0
0
101
761
1.98
3.78
4.0
3.2
72.13
54.32
ug/l
0.54
94
721
99
742
1.96
3.75
12.2
8.0
2.04
2.08
e9/l
0.21
91
655
8
12
6.97
3.72
2.9
5.2
2.22
2.17
mmol/l
—
8
12
96
716
1.92
3.65
12.4
8.1
0.04
0.04
e9/l
0.12
86
609
98
741
1.91
3.52
14.2
8.5
0.16
0.18
e9/l
0.78
88
639
95
713
1.89
3.47
12.0
7.9
32.87
32.07
%
0.31
90
692
89
655
1.87
3.45
6.2
6.2
6.08
6.22
mmol/l
0.24
83
592
106
827
1.93
3.40
4.3
3.9
36.03
36.67
mmol/mol
0.31
97
780
24
111
2.38
3.34
4.8
13.7
107.00
105.78
mmol/l
0.28
24
111
91
679
1.85
3.33
12.4
8.1
2.72
2.73
%
0.00
86
651
90
675
1.82
3.18
12.5
8.1
0.63
0.63
%
0.00
85
652
108
859
1.89
3.13
3.8
3.0
1.17
1.13
mmol/l
0.22
99
816
101
789
1.83
3.08
15.6
10.2
3.33
3.81
e9/l
2.15
89
669
90
683
1.78
2.98
12.5
8.2
8.65
8.32
%
0.79
84
657
69
486
1.77
2.95
14.0
10.1
1.22
1.22
mmol/l
0.06
69
462
133
1150
2.25
2.85
8.3
4.8
1.78
1.83
mu/l
0.16
125
1076
90
690
1.75
2.82
16.9
10.2
0.00
0.00
e9/l
-0.00
75
551
34
195
1.96
2.77
11.1
7.8
7.37
7.37
ph
0.01
25
125
8
19
4.38
2.72
1.0
1.2
10.09
8.17
mg/l
—
8
19
113
934
1.82
2.63
3.9
3.4
1.47
1.46
mmol/l
0.12
101
881
30
168
1.98
2.61
13.2
14.3
—
—
—
0
0
114
947
1.82
2.58
4.1
3.5
4.46
4.46
mmol/l
0.02
105
896
57
397
1.70
2.45
3.1
2.6
—
—
—
0
0
113
944
1.77
2.42
4.3
3.6
2.70
2.66
mmol/l
0.24
102
891
8
22
3.78
2.40
1.9
2.3
42.18
36.39
%
—
8
22
114
961
1.75
2.29
4.1
3.2
5.48
5.48
mmol/l
0.01
105
879
54
377
1.67
2.27
5.2
3.4
0.22
0.32
e6/l
0.27
40
268
5
9
5.70
2.23
15.4
5.1
16.33
26.10
ug/l
—
5
9
52
368
1.63
2.05
4.1
2.6
—
—
—
0
0
59
432
1.60
2.02
17.4
7.7
—
—
—
0
0
58
423
1.60
2.02
5.4
3.4
32.96
204.74
e6/l
0.55
43
311
67
506
1.58
2.01
6.6
4.1
30.72
74.88
e6/l
1.03
46
321
12
51
2.47
2.00
2.4
8.4
0.54
0.59
%
0.22
12
51
40
270
1.65
1.88
4.7
3.4
7.40
7.39
ph
0.38
30
191
19
104
1.95
1.77
4.7
16.4
1.66
1.13
mmol/l
1.31
19
99
0
48
0.00
1.73
0.0
1.7
—
5.99
—
0
13
5
13
3.94
1.73
2.4
1.2
67.32
42.55
nmol/l
—
5
13
50
365
1.55
1.69
2.6
2.8
3.49
2.45
mg/l
1.83
42
304
32
210
1.66
1.67
4.0
3.2
—
—
—
0
0
5
14
3.65
1.63
13.6
2.5
24.26
42.50
mmol/l
—
5
14
50
369
1.53
1.60
5.1
3.4
—
—
estimate
—
0
0
12
57
2.20
1.60
1.2
1.2
—
—
—
0
0
6
20
3.08
1.59
3.0
12.1
12.13
12.23
%
—
6
20
30
197
1.65
1.56
10.5
8.9
1.17
1.24
mmol/l
1.02
30
184
138
1272
1.92
1.53
18.8
12.1
63.28
64.05
umol/l
0.18
138
1249
7
27
2.67
1.53
2.7
9.7
61.43
67.61
%
—
7
27
7
28
2.57
1.47
1.3
1.3
—
—
—
0
0
5
120
0.40
1.45
2.4
1.3
—
—
—
0
0
138
1279
1.86
1.40
17.9
11.9
17.50
23.11
mg/l
1.82
112
976
46
343
1.49
1.38
7.2
8.8
1.11
1.11
inr
0.00
38
293
132
1210
1.69
1.37
24.0
15.6
331.89
333.43
g/l
1.25
132
1202
22
138
1.69
1.35
2.3
1.5
—
—
—
0
0
23
147
1.67
1.32
13.8
6.5
—
—
—
0
0
34
240
1.54
1.32
2.0
3.7
1.19
1.65
mg/l
0.40
23
166
32
223
1.55
1.31
3.0
3.4
12.79
3.85
e6/l
0.34
14
113
28
189
1.59
1.31
13.9
12.7
26.01
24.83
mmol/l
0.97
28
189
16
93
1.81
1.27
2.4
1.8
0.00
0.00
estimate
—
5
25
5
19
2.68
1.22
1.4
2.6
—
—
—
0
0
6
26
2.36
1.20
2.5
2.7
88.58
92.40
%
—
6
26
5
21
2.43
1.10
5.2
6.2
—
—
—
0
0
7
33
2.17
1.07
1.7
5.9
37.00
36.91
°c
—
7
33
64
531
1.35
1.02
5.4
3.2
6.46
6.32
ph
0.38
36
258
24
166
1.53
1.02
9.4
7.4
0.83
0.81
mmol/l
0.31
24
159
18
117
1.61
0.99
1.4
1.4
—
—
—
0
0
0
29
0.00
0.99
0.0
1.1
—
—
—
0
0
96
851
1.35
0.97
7.4
4.3
—
—
—
0
0
18
120
1.57
0.90
1.1
1.5
—
—
—
0
0
41
325
1.36
0.86
6.5
3.3
0.00
0.00
estimate
-0.00
17
126
33
254
1.38
0.83
4.3
3.2
11.22
23.79
ng/l
3.05
18
122
6
32
1.91
0.82
4.5
4.4
—
—
—
0
0
14
91
1.59
0.78
2.0
2.3
—
—
—
0
0
24
177
1.42
0.77
14.2
6.0
7.40
7.42
ph
1.35
24
139
9
54
1.71
0.76
2.0
1.8
—
—
—
0
0
7
39
1.83
0.73
4.0
2.8
59.06
55.20
%
—
7
39
5
25
2.03
0.73
2.6
1.7
—
—
—
0
0
5
25
2.03
0.73
2.6
1.7
—
—
—
0
0
5
25
2.03
0.73
2.6
1.7
—
—
—
0
0
5
25
2.03
0.73
2.6
1.7
—
—
—
0
0
9
58
1.59
0.71
2.4
1.7
—
—
—
0
0
5
28
1.81
0.67
2.8
2.3
—
—
—
0
0
40
330
1.29
0.64
6.3
3.4
—
—
—
0
0
60
524
1.24
0.60
4.0
3.1
—
—
estimate
—
0
0
0
22
0.00
0.60
0.0
1.1
—
0.51
—
0
22
134
1282
1.38
0.59
13.4
9.4
—
—
—
0
0
29
233
1.30
0.56
8.1
4.2
—
—
—
0
0
14
99
1.46
0.56
2.2
1.7
1.04
1.09
g/l
0.09
14
94
20
152
1.36
0.55
1.8
1.5
—
—
—
0
0
39
327
1.26
0.55
4.7
2.9
1.02
1.02
kg/l
0.36
30
190
13
91
1.47
0.55
4.2
15.5
7.45
7.44
ph
—
7
47
6
39
1.56
0.53
1.3
1.1
—
—
—
0
0
30
246
1.27
0.51
2.0
1.6
—
—
—
0
0
20
157
1.32
0.46
3.3
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
5.9
—
23.35
—
0
17
0
19
0.00
0.39
0.0
2.7
—
112.16
—
0
19
0
19
0.00
0.39
0.0
3.7
—
26.69
—
0
13
5
36
1.40
0.38
1.4
2.7
—
—
—
0
0
10
72
1.42
0.38
5.5
2.9
—
—
—
0
0
21
172
1.26
0.36
3.5
3.3
43.14
860.47
ng/l
—
7
90
71
655
1.16
0.36
6.3
3.5
0.00
0.00
estimate
-0.00
16
128
10
73
1.40
0.35
1.5
1.6
—
—
—
0
0
43
383
1.17
0.34
2.0
1.8
1.22
1.25
mmol/l
0.12
38
343
6
46
1.32
0.33
1.0
1.6
—
—
—
0
0
10
74
1.38
0.33
1.5
1.5
—
—
—
0
0
52
472
1.15
0.32
1.8
1.7
—
—
—
0
0
70
650
1.14
0.31
6.4
3.4
0.00
0.00
estimate
-0.00
18
128
14
111
1.29
0.31
1.2
1.4
—
—
—
0
0
69
642
1.14
0.30
6.5
3.5
0.00
0.00
estimate
-0.00
18
129
7
57
1.24
0.29
6.1
22.4
0.46
0.64
%
—
7
57
34
302
1.16
0.28
6.8
4.8
—
—
—
0
0
9
74
1.23
0.26
1.1
1.1
—
—
—
0
0
45
412
1.13
0.24
2.1
1.8
—
—
—
0
0
20
172
1.19
0.23
1.3
1.2
39.94
6.63
u/ml
—
7
68
5
38
1.33
0.23
1.4
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
3.3
—
—
—
0
0
42
386
1.12
0.21
2.2
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
0.51
—
0
12
0
12
0.00
0.21
0.0
1.1
—
23.07
—
0
12
0
13
0.00
0.21
0.0
1.2
—
181.08
—
0
13
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
51
1.18
0.19
2.0
1.8
18.00
61.26
u/ml
—
6
51
15
128
1.19
0.19
1.7
2.1
—
—
—
0
0
7
58
1.22
0.18
6.1
22.2
96.87
96.03
%
—
7
58
7
59
1.20
0.18
6.1
21.8
1.20
1.18
%
—
7
59
30
273
1.12
0.18
2.4
3.2
90.48
82.22
ug/g
0.09
22
200
7
62
1.14
0.17
2.0
2.5
1.24
1.23
mmol/l
—
7
52
21
189
1.13
0.14
1.5
1.3
20.00
22.31
iu/ml
—
5
39
52
497
1.07
0.11
1.8
1.6
2.10
1.78
g/l
0.46
27
267
20
183
1.11
0.10
3.5
2.5
23362.14
6534.84
u/l
—
9
69
56
538
1.06
0.10
1.5
1.8
0.50
2.32
u/ml
1.93
14
107
5
43
1.17
0.10
1.8
1.1
—
—
—
0
0
5
43
1.17
0.10
1.2
1.7
—
—
—
0
0
18
196
0.91
0.09
1.8
2.0
—
—
—
0
0
18
195
0.91
0.08
1.8
2.0
—
—
—
0
0
18
195
0.91
0.08
1.6
2.0
—
—
—
0
0
7
67
1.05
0.08
1.6
1.2
—
—
—
0
0
50
517
0.95
0.07
2.8
2.4
—
—
—
0
0
17
183
0.92
0.07
1.8
2.0
—
—
—
0
0
36
345
1.06
0.07
4.5
2.7
0.21
0.00
estimate
0.47
14
102
9
102
0.88
0.06
6.9
3.3
—
—
—
0
0
47
461
1.03
0.02
6.4
3.1
0.27
0.01
estimate
0.45
15
104
35
343
1.03
0.01
2.0
1.8
—
—
—
0
0
39
391
1.00
0.00
1.6
1.7
—
—
—
0
0
19
193
0.98
0.00
1.7
2.0
—
—
—
0
0
37
375
0.98
0.00
2.4
2.2
—
—
—
0
0
17
175
0.97
0.00
1.6
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
98.83
—
0
6
0
6
0.00
0.00
0.0
1.8
—
26.18
—
0
6
0
6
0.00
0.00
0.0
1.0
—
128.17
—
0
6
0
6
0.00
0.00
0.0
1.3
—
8.65
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
8
85
0.94
-0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
8.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
8.88
—
0
9
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
21
210
1.00
-0.00
1.1
1.3
—
—
—
0
0
12
120
1.00
-0.00
1.2
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
82
0.97
-0.00
1.6
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
6.51
—
0
8
0
8
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
100.00
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PUBDISNAS and mortality.

Females

Parameter HR [95% CI] p-value
E4_PUBDISNAS 2.209 [1.53, 3.18] < 0.001
Birth year 0.992 [0.98, 1.0] 0.079

During the follow-up period (1.1.1998 — 31.12.2019), 97 out of 1798 females with E4_PUBDISNAS died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_PUBDISNAS.

N-year risk Females Males
1 0.179% No data
5 1.09% No data
10 2.848% No data
15 5.741% No data
20 9.391% No data

Relationships between endpoints

↥

Index endpoint: E4_PUBDISNAS – Disorders of puberty, other/unspecified

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data